Brookline Capital Markets Forecasts CLRB Q3 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Stock analysts at Brookline Capital Markets increased their Q3 2026 earnings estimates for Cellectar Biosciences in a research note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, up from their prior forecast of ($0.50). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.39) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ FY2027 earnings at ($2.35) EPS.

Several other brokerages have also recently issued reports on CLRB. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research note on Thursday, October 15th. Wall Street Zen lowered Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Cellectar Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Cellectar Biosciences Trading Down 0.8%

Shares of NASDAQ CLRB opened at $1.21 on Thursday. The business’s 50 day moving average is $1.68 and its 200-day moving average is $2.54. Cellectar Biosciences has a 1-year low of $1.11 and a 1-year high of $4.70.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.10.

About Cellectar Biosciences

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue. The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.